



LEI: 549300Q7EXQQH6KF7Z84

17 January 2025

**RTW Biotech Opportunities Ltd**

**New Investment in Series A of Windward Bio**

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note a new portfolio company investment in **Windward Bio** ("Windward"), a Swiss private, clinical-stage drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The Series A round raised 200 million in funds which will support the advancement of two undisclosed programs through Investigational New Drug (IND)-enabling studies.

Windward has entered into an agreement to license WIN378 from Hong Kong-listed Kelun-Biotech and Harbour BioMed for global rights, excepting China and select smaller markets in Asia. Windward is preparing to begin a phase 2 trial investigating WIN378 in severe asthma with initial clinical readouts expected in 2026. Additional clinical trials are planned in asthma and chronic obstructive pulmonary disease (COPD), aiming to address unmet needs in approximately 5 million advanced, uncontrolled patients in the US, Europe, and Japan.

**Roderick Wong, Managing Partner and CIO** at RTW Investments, LP, the Investment Manager said, "We are thrilled to support the seasoned team at Windward Bio in the development of their pipeline and particularly WIN378, a next-generation TSLP therapy, which has the potential to improve convenience and treatment outcomes for patients with severe respiratory diseases "

The full text of the announcement can be accessed at <https://windwardbio.com>.

**For Further Information**

**RTW Investments, LP**

**+44 20 7959 6361**

Woody Stileman, Managing Director, Business Development

[biotechopportunities@rtwfunds.com](mailto:biotechopportunities@rtwfunds.com)

Krishna McCune, Director, Investor Relations

**Cadarn Capital (PR & Communications/Distribution & IR Partner)**

**+44 79 8418 4461**

Lucy Clark (PR)

[Lucy@cadarncapital.com](mailto:Lucy@cadarncapital.com)

David Harris (Distribution)

**+44 73 6888 3211**

[david@cadarncapital.com](mailto:david@cadarncapital.com)

**Deutsche Numis (Joint Corporate Broker)**

**+44 20 7260 1000**

Freddie Barnfield

Nathan Brown

Euan Brown

**BofA Securities (Joint Corporate Broker)**

**+44 20 7628 1000**

Edward Peel

Alex Penney

**Elysium Fund Management Limited**

**+44 14 8170 3100**

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

**Morgan Stanley Fund Services USA LLC**

**+1 914 225 8885**

**About Biotech Opportunities Ltd:**

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at [www.rtwfunds.com/rtw-biotech-opportunities-ltd](http://www.rtwfunds.com/rtw-biotech-opportunities-ltd) for more information.

\*\*\*\*\*

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

\*\*\*\*\*

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCGPUCGGUPAGMQ